Absolutely if we meet our endpoint yes it should.
Post# of 155276
(Total Views: 584)
Posted On: 12/15/2021 9:22:01 PM
Absolutely if we meet our endpoint yes it should. Nash is very hard to treat. It’s actually very surprising before the NASH data the share price hasn’t gone up. Maybe the next week you’ll see shorts covering and some pre data buying before the top line data is out.
I know people say only way the SP goes up is sales but data is very important as well. I know we are on OTC and shorts are all over but of the data is good watch out.
If the data is confusing and not clear as mud the I expect the opposite. We need a good top line report and personally some actual good coverage on the data.
I know people say only way the SP goes up is sales but data is very important as well. I know we are on OTC and shorts are all over but of the data is good watch out.
If the data is confusing and not clear as mud the I expect the opposite. We need a good top line report and personally some actual good coverage on the data.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Federal Whistleblower
SEC Submission HL-1412396
DOJ Ref #20250705-0001
SEC Submission HL-1412396
DOJ Ref #20250705-0001